CRISTINA POVEDA to Humans
This is a "connection" page, showing publications CRISTINA POVEDA has written about Humans.
Connection Strength
0.177
-
Parasite-microbiota interactions: a pathway to innovative interventions for Chagas disease, leishmaniasis, and ascariasis. Future Microbiol. 2025 Feb; 20(2):149-161.
Score: 0.024
-
Generation and Characterization of In Vitro Transcribed mRNA. Methods Mol Biol. 2024; 2786:147-165.
Score: 0.023
-
Mining the Metabolome for New and Innovative Chagas Disease Treatments. Trends Pharmacol Sci. 2021 01; 42(1):1-3.
Score: 0.018
-
Interaction of Signaling Lymphocytic Activation Molecule Family 1 (SLAMF1) receptor with Trypanosoma cruzi is strain-dependent and affects NADPH oxidase expression and activity. PLoS Negl Trop Dis. 2020 09; 14(9):e0008608.
Score: 0.018
-
A systematic review of the Trypanosoma cruzi genetic heterogeneity, host immune response and genetic factors as plausible drivers of chronic chagasic cardiomyopathy. Parasitology. 2019 03; 146(3):269-283.
Score: 0.016
-
Ecology of Trypanosoma cruzi I genotypes across Rhodnius prolixus captured in Attalea butyracea palms. Infect Genet Evol. 2017 04; 49:146-150.
Score: 0.014
-
Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 Dec; 20(12):e1012764.
Score: 0.006
-
The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
Score: 0.006
-
Adaptation of Chagas Disease Screening Recommendations for a Community of At-risk HIV in the United States. Clin Infect Dis. 2024 02 17; 78(2):453-456.
Score: 0.006
-
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
Score: 0.005
-
Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
Score: 0.005
-
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
Score: 0.005
-
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
Score: 0.005
-
Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
Score: 0.005
-
SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
Score: 0.005
-
Autoantibodies against the immunodominant sCha epitope discriminate the risk of sudden death in chronic Chagas cardiomyopathy. Ann N Y Acad Sci. 2021 08; 1497(1):27-38.
Score: 0.005
-
Prevalence of Trypanosoma cruzi's Discrete Typing Units in a cohort of Latin American migrants in Spain. Acta Trop. 2016 May; 157:145-50.
Score: 0.003
-
Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection. PLoS Negl Trop Dis. 2015; 9(8):e0004025.
Score: 0.003
-
Cytokine profiling in Chagas disease: towards understanding the association with infecting Trypanosoma cruzi discrete typing units (a BENEFIT TRIAL sub-study). PLoS One. 2014; 9(3):e91154.
Score: 0.003
-
Distribution of Trypanosoma cruzi discrete typing units in Bolivian migrants in Spain. Infect Genet Evol. 2014 Jan; 21:440-2.
Score: 0.003